Effort of canagliflozin on metabolic syndrome parameters and biomarkers of heart, kidney and vascular diseases in patients with type 2 diabetes mellitus.

Effort of canagliflozin on metabolic syndrome parameters and biomarkers of heart, kidney and vascular diseases in patients with type 2 diabetes mellitus. - Effort of canagliflozin on metabolic syndrome parameters and biomarkers of heart, kidney and vascular diseases in patients with type 2 diabetes mellitus.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000018151

Enrollment

100

Registered

2015-07-06

Start date

2014-10-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) HbA1c >=6.5% and <10%, and a fasting plasma glucose (FPG) of <=270 mg/dL (HbA1c >=7.0% in case of having sulfonylureas). 2) BMI >=25kg/m2. 3) Patients receiving sulphonylureas, thiazolidinediones, biguanides and/or DPP4 inhibitors more than 8 weeks 4) Patients with blood pressure >=130/80 mmHg (systolic/diastolic). 5) Patients who have given written informed consent atenrollment.

Exclusion criteria

Exclusion criteria: 1) Patients with allergy for canagliflozin. 2) Patients with severe ketosis, diabetic coma, diabetic precoma, or type 1 diabetes mellitus. 3) Patients with severe renal dysfunction (eGFR<30) including the patient who needs haemodialysis or peritoneal dialysis. 4) Patients with severe infection disease or serious trauma. 5) Patient with the history of an urinary tract infection or genital infection. 6) Pregnant women and women suspected of being pregnant. 7) Women during lactation. 8) Patient who had myocardial infarction or cerebral infarction within 3 months before the informed consent. 9) Patients with insulin therapy. 10) Patients whose doctor judges to unfit for this study.

Design outcomes

Primary

Measure	Time frame
1) HbA1c, fasting blood glucose, HOMA-R and HOMA-beta 2) Body weight, adiponectin, triglyceride, remnant-like particle cholesterol and apoB-48 3) BNP and troponin 4) Cystatin C, albuminuria, L-FABP and NGAL 5) High-sensitivity CRP 6) Symptoms and laboratory test values	—

Countries

Japan

Contacts

Public ContactHiroyuki Naruse

Fujita Health University School of Medicine Department of Joint Research Laboratory of Clinical Medicine

hnaruse@fujita-hu.ac.jp81-0562-93-2312

Outcome results